Last Updated on October 6, 2024 by The Health Master
USFDA approval
Sun Pharmaceutical Industries Ltd. has made a significant stride in the treatment of hair loss with the US Food and Drug Administration approval (USFDA approval) of Leqselvi (deuruxolitinib) tablets.
This groundbreaking medication is specifically designed to address severe alopecia areata, an autoimmune condition that causes patchy or complete baldness.
Understanding Alopecia Areata
Alopecia areata, a distressing condition affecting approximately 2.5% of the US population, occurs when the immune system mistakenly attacks hair follicles.
This leads to hair loss on the scalp and sometimes other parts of the body.
Until now, treatment options for this autoimmune disorder have been limited, leaving many patients seeking effective solutions.
Leqselvi: A New Hope
Leqselvi, an oral medication, works by inhibiting Janus Kinases (JAK) 1 and JAK2, enzymes involved in immune responses.
By targeting these specific enzymes, the drug helps to regulate the immune system and promote hair regrowth.
Sun Pharma’s CEO of North America Business, Abhay Gandhi, expressed enthusiasm about thedrug’s potential, stating that preparations for commercialization were already underway.
With Leqselvi, Sun Pharma aims to expand its global specialty business, which recently surpassed the $1 billion sales mark.
Clinical Trials Demonstrate Effectiveness
The USFDA approval of Leqselvi was based on robust clinical data from two large-scale Phase 3 trials involving over 1,200 patients with severe alopecia areata.
These trials demonstrated that a significant number of patients who took Leqselvi experienced substantial hair regrowth within 24 weeks.
In fact, up to 25% of participants achieved almost complete hair restoration.
A Promising Future
The USFDA approval of Leqselvi marks a significant milestone in the treatment of alopecia areata.
This innovative medication offers new hope for patients who have long struggled with hair loss.
Sun Pharma’s commitment to developing effective therapies for dermatological conditions is evident with the addition of Leqselvi to its portfolio.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA approval granted for Valsartan Tablets
USFDA approval granted for Fluphenazine Hydrochloride Tablets USP
USFDA approval granted for Topiramate Capsules USP
USFDA approval granted for the drug used for Colon Cleansing
USFDA approval granted for the drug for the treatment of Migraine
USFDA approval granted for this chronic heart failure treatment drug
Pharma Industry seeks relief from Sudden Price Changes of medicines
Govt Job: For Drugs Inspector under Public Service Commission
Pharma Companies get more time to clean up their Act
USFDA issues warning letter to Brassica Pharma, Maharashtra
Indian Govt vigilant about quality of medicines: HM
FSSAI: Food Labelling and Display – Chapter-8
Telangana DCA busts illegal API Manufacturing Unit
How to protect your medications during Summers
CDSCO approval granted for New Drug for Diabetic Foot Ulcers
Govt targets Rs. 90,000 crore Pharma Industry under PLI scheme
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
